Phase 2Phase 3RegistrationApproved in 2017 Fremanezumab (anti CGRP) Post-Traumatic Headache Fasinumab1 Chronic lower back pain Laquinimod Huntington disease Fremanezumab (anti CGRP) Cluster Headache Fasinumab1 Osteoarthritis pain Austedo® (SD-809)2 Tourette syndrome (U.S.) Reslizumab SC3 Asthma (Global) Fremanezumab (anti CGRP) Migraine (U.S & E.U.) Azilect®4 Parkinson's disease (Japan) ProAir® e-Respiclick® E-connectivity (U.S) CT-P10 *** (rituximab biosimilar) CT-P6 *** (trstuzumab biosimilar) BENDEKA ®6 CLL and NHL (Growth Markets) Austedo ® Huntington Disease (U.S.) Austedo ® Tardive dyskinesia(U.S.) ArmonAir ® RespiClick ® Asthma (U.S.) AirDuo ® RespiClick® Asthma (U.S.) QVAR® RediHaler (beclomethasone diproprionate HFA) Asthma (U.S.) Reslizumab IV 3 Asthma (selective Growth Markets)